Oxacillin Sodium |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Usual Diluents |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NS, D5W | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[250 mg] [50 ml] [30 min] [500 mg] [50 ml] [30 min] [1000 mg] [50 ml] [30 min] [2000 mg] [50-100 ml] [30 min]* *Infusion time may be increased to 60 minutes if the patient experiences pain or discomfort at the injection site assuming that the patient has a patent IV site. Also available as a premixed IV: 2G3538 NDC 0338-1013-41 1 gram oxacillin |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stability / Miscellaneous |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dosing (Adults): 250 to 500 mg IM or IV every 4 to 6 hours (mild to moderate infections). 1 gram IM or IV every 4 to 6 hours (severe infections). Dosing adjustment in renal impairment: Pharmacokinetics Oxacillin Sodium binds to serum protein, mainly albumin. The degree of protein binding reported varies with the method of study and the investigator, but generally has been found to be 94.2 ± 2.1%. Intramuscular injections give peak serum levels 30 minutes after injection. A 250 mg dose gives a level of 5.3 µg/mL while a 500 mg dose peaks at 10.9 µg/mL. Intravenous injection gives a peak about 5 minutes after the injection is completed. Slow IV dosing with 500 mg gives a 5 minute peak of 43 µg/mL with a half-life of 20 to 30 minutes. INDICATIONS AND USAGE The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. Directions for Use of GALAXY Plastic Container For Intramuscular Use For Direct Intravenous Use For Administration by Intravenous Drip --- Storage/Stability --- STABILITY PERIODS FOR OXACILLIN FOR INJECTION, USP
Stability studies on Oxacillin Sodium at concentrations of 0.5 mg/mL and 2 mg/mL in various intravenous solutions listed below indicate the drug will lose less than 10% activity at room temperature (70° F) during a 6-hour period. IV Solution Only those solutions listed above should be used for the intravenous infusion of Oxacillin Sodium. The concentration of the antibiotic should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of oxacillin is administered before the drug loses its stability in the solution in use. If another agent is used in conjunction with oxacillin therapy, it should not be physically mixed with oxacillin but should be administered separately. Pharmacy Bulk Package HOW SUPPLIED Revised 01-2004Manufactured by Source: [package insert] |